通过感染和接种疫苗产生的针对新冠病毒奥密克戎BA.1的中和免疫力。
Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
作者信息
Duan Li-Jun, Jiang Wen-Guo, Wang Zhuang-Ye, Yao Lin, Zhu Ka-Li, Meng Qing-Chuan, Wang Bao-Shan, Li Li-Bo, Wang Guo-Lin, Ma Mai-Juan
机构信息
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Jining Center for Disease Control and Prevention, Jining, China.
出版信息
iScience. 2022 Sep 16;25(9):104886. doi: 10.1016/j.isci.2022.104886. Epub 2022 Aug 9.
The emergence of the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant has raised questions regarding resistance to neutralizing antibodies elicited by natural infection or immunization. We examined the neutralization activity of sera collected from previously SARS-CoV-2-infected individuals and SARS-CoV-2 naive individuals who received BBIBP-CorV or CoronaVac to BA.1 and the earlier variants Alpha, Beta, and Delta. Both sera from convalescent patients over three months after infection and two-dose BBIBP-CorV or CoronaVac vaccine recipients barely inhibited BA.1, less effectively neutralized Beta and Delta, and moderately neutralized Alpha. However, administering a single dose of BBIBP-CorV or CoronaVac in previously infected individuals or a third dose booster vaccination of BBIBP-CorV or CoronaVac in previously vaccinated individuals enhances neutralizing activity against BA.1 and other variants, albeit with a lower antibody titer for BA.1. Our data suggest that a booster vaccination is important to broaden neutralizing antibody responses against the variants.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎BA.1（B.1.1.529）变体的出现引发了关于对自然感染或免疫接种所诱导的中和抗体产生抗性的问题。我们检测了从先前感染过SARS-CoV-2的个体以及接种过BBIBP-CorV或科兴疫苗的未感染过SARS-CoV-2的个体中采集的血清对BA.1以及早期变体阿尔法、贝塔和德尔塔的中和活性。感染后三个月以上的康复患者的血清以及两剂BBIBP-CorV或科兴疫苗接种者的血清几乎都不能抑制BA.1，对贝塔和德尔塔的中和效果较差，对阿尔法的中和效果中等。然而，在先前感染过的个体中接种一剂BBIBP-CorV或科兴疫苗，或在先前接种过疫苗的个体中接种第三剂BBIBP-CorV或科兴疫苗加强针，可增强对BA.1和其他变体的中和活性，尽管对BA.1的抗体滴度较低。我们的数据表明，加强疫苗接种对于扩大针对这些变体的中和抗体反应很重要。
Zotero 插件